Impact of intravascular ultrasound‐guided drug‐eluting stent implantation on patients with chronic kidney disease: Results from ULTIMATE trial

2019 ◽  
Author(s):  
Junjie Zhang ◽  
Xiaofei Gao ◽  
Zhen Ge ◽  
Leng Han ◽  
Shu Lu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Intravascular Ultrasound ◽  
Stent Implantation ◽  
Drug Eluting Stent ◽  
Ultrasound Guided ◽  
Drug Eluting

scholarly journals Effect of Intravascular Ultrasound–Guided Drug-Eluting Stent Implantation

2020 ◽  
Vol 13 (1) ◽  
pp. 62-71 ◽  
Author(s):  
Sung-Jin Hong ◽  
Gary S. Mintz ◽  
Chul-Min Ahn ◽  
Jung-Sun Kim ◽  
Byeong-Keuk Kim ◽  
...  
Keyword(s):  
Intravascular Ultrasound ◽  
Stent Implantation ◽  
Drug Eluting Stent ◽  
Ultrasound Guided ◽  
Drug Eluting

Intravascular ultrasound-guided drug-eluting stent implantation

2019 ◽  
Vol 67 (4) ◽  
Author(s):  
Evan Shlofmitz ◽  
Kayode O. Kuku ◽  
Ron Waksman ◽  
Hector M. Garcia-Garcia
Keyword(s):  
Intravascular Ultrasound ◽  
Stent Implantation ◽  
Drug Eluting Stent ◽  
Ultrasound Guided ◽  
Drug Eluting

Impact of Intravascular Ultrasound–Guided Optimal Stent Expansion on 3-Year Hard Clinical Outcomes

2021 ◽  
Vol 14 (10) ◽  
Author(s):  
Yong-Joon Lee ◽  
Jun-Jie Zhang ◽  
Gary S. Mintz ◽  
Sung-Jin Hong ◽  
Chul-Min Ahn ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Intravascular Ultrasound ◽  
Stent Implantation ◽  
Hazard Ratio ◽  
Drug Eluting Stent ◽  
Lumen Area ◽  
Ultrasound Guided ◽  
Stent Expansion ◽  
Drug Eluting

Background: Although stent underexpansion on intravascular ultrasound (IVUS) has been a major predictor for adverse outcomes in previous studies, these studies have primarily focused on angiographic restenosis or repeat revascularization with short-term follow-up. This study sought to evaluate the long-term benefit of different criteria for IVUS-defined optimal stent expansion on hard clinical outcomes. Methods: From the pooled data of 2 randomized trials, IVUS-XPL (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions) and ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-Comers Coronary Lesions) that compared IVUS- versus angiography-guided drug-eluting stent implantation, a total of 1254 patients with IVUS-guided drug-eluting stent implantation into 1484 long lesions (implanted stent length, ≥28 mm) were included. Different criteria for IVUS-defined optimal stent expansion based on minimum stent area (MSA) as an absolute measure or MSA relative to reference lumen area were applied and validated. The primary end point was composite of cardiac death, target lesion–related myocardial infarction, or stent thrombosis at 3 years. Results: The rate of the primary end point was lower in patients with optimal stent expansion versus those without optimal stent expansion according to 3 IVUS-defined optimal stent expansion criteria: MSA >5.5 mm 2 (0.5% versus 2.2%; hazard ratio, 0.21 [95% CI, 0.06–0.75]; P =0.008), MSA >5.0 mm 2 (0.6% versus 2.6%; hazard ratio, 0.24 [95% CI, 0.09–0.68]; P =0.003), and MSA/distal reference lumen area >90% (0.5% versus 2.4%; hazard ratio, 0.32 [95% CI, 0.12–0.88]; P =0.019). Achieving other relative expansion criteria, MSA/distal reference lumen area >100% or 80% or MSA/average reference lumen area >90% or 80%, was not associated with a reduction in hard clinical events. Conclusions: In patients undergoing IVUS-guided drug-eluting stent implantation for long lesions, achieving optimal stent expansion of MSA >5.5 mm 2 , >5.0 mm 2 , or MSA/distal reference lumen area >90% was associated with improved long-term hard clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document